Journal of Biomedical Sciences
Research Article Peer-review, Open Access

Clostridium Difficile Toxin with Different Disease Symptoms and Location of the Body

Walaa Shakir Mahmood [1]

Abstract

Clostridium difficile (C. difficile) is a type of Gram-positive, spore-forming, anaerobic bacillus found throughout the environment. intestinal system of both humans and animals as well as within the surrounding surroundings. In the past ten years, the occurrence and seriousness of C. difficile have increased. Infection rates are on the rise globally, making it among the most frequent hospital-acquired infections. Sending this information The transmission of the pathogen happens through the fecal-oral route, with key risk factors being antibiotic treatment, advanced age, and healthcare settings. residence in a nursing facility. Clinical presentation varies, ranging from being an asymptomatic carrier to experiencing a wide range of symptoms. diarrhea, escalating to severe colitis that can be fatal. Diagnosis relies on the direct identification of C. difficile. Detecting toxins in feces is usually done using the EIA assay, however, no single test can fully confirm a case of CDI.

The preferred antibiotics are vancomycin, fidaxomicin, and metronidazole, with metronidazole being deemed less effective. The objective

The purpose of this review is to provide physicians with updated scientific information on C. difficile infection, with a particular emphasis on fecal microbiota. transplantation is a therapy that shows great potential.

Infection by C. difficile is a prevalent and expensive healthcare-related infection. Infection outside the intestines is not commonly found. We describe a special instance of abscess in the abdominal wall that occurred six months after gastrointestinal (GI) surgery. The patient underwent CT-guided drainage of the abscess, insertion of a drainage catheter, and received extensive antibiotic therapy across several hospital stays.The prevalence of C. difficile infection is on the rise globally. Prevention is multifaceted, demonstrating a intricate and changing epidemiological landscape, but these recommendations do not specifically cover the situation in low- and middle-income countries (LMIC). Despite this, the occurrence of C. difficile in LMIC probably matches, if not surpasses, that of wealthy countries, and LMIC may face extra difficulties in diagnosing and controlling C. difficile. The ISID brought together a group of experts to assess the current global situation of C. difficile infections and create evidence-based suggestions for preventing infections that can be widely applied.

Keyword: Clostridium difficile-toxin-disease.

[1] Baghdad University –College of Science –Biotechnology department, Iraq

World of Medicine: Journal of Biomedical Sciences Vol .1 No.11 (2024)
https://wom.semanticjournals.org/index.php/biomed

Introduction

C. difficile, a bacterium that creates spores and thrives in the absence of oxygen, is present in the usual gut bacteria at low levels (3% in people who arenotill).16 to 35% of adults who are hospitalized are patients. Roughly 50% to 66% of young children often have asymptomatic colonization.

Finding *C. difficile* in solid feces suggests the presence of the bacteria in infants but does not always signify an infection. The existence of toxins (Toxins A and B) causes the development of *C. difficile* digestive tract infection.

Clostridioides difficile is one of the common healthcare-associated infections (1) Within affluent countries, there are rigorous measures established for the surveillance and prevention of *C. difficile*, based on specific guidelines for detecting, treating, and controlling infections from this challenging bacteria (2). The sudden increase of C. difficile in the early 2000s, along with the more serious sickness associated with the Nap-1/027 strain epidemic, led hospitals, healthcare providers, and regulatory agencies in many wealthy countries to respond . In the UK, media coverage focused on deaths from *C. difficile* in hospitals with insufficient staffing and poor cleanliness, resulting in administrators being fired, calls for legal action, and limitations on certain antibiotics. *C. difficile* RT-017 appears to be the prevalent strain in different parts of Asia, with documented instances of transmission between humans (3). Responses to outbreaks of *C. difficile* indicate that the disease is impacted by various elements, with efforts targeting the environment, host/microbiome, and the pathogen.

C. difficile, a gram-positive bacterium that forms spores, is responsible for causing infectious diarrhea and pseudomembranous colitis, resulting in a high rate of illness and mortality. Elderly individuals who have received antibiotics and are in the hospital are at highest risk of contracting *C. difficile* infection. The risk of *C. difficile* is heightened in these individuals due to a reduction in helpful gut bacteria from antibiotics and a compromised immune system from old age and other health issues. Most of the outbreaks happen in hospitals and long-term care facilities, but cases acquired in outpatient settings have also been documented. The emergence of highly virulent strains of *C. difficile* is now having a broader effect on a larger population within North America and Europe, including younger individuals. Although uncommon in Asia traditionally, this pathogen has the potential to quickly spread and become more common in areas where it was once rare resulting from an overabundance of *C. difficile* in a susceptible person. The causes are intricate, encompassing shifts in gut microbiota triggered by Utilizing antibiotics, decreasing stomach acidity, inserting feeding tubes in the stomach or small intestine, compromised immune system. cancer, transplantation, or potentially inflammatory bowel disease. The highest risk of *C. difficile* infection (CDI) was linked to fluroquinolones and cephalosporins; however, CDI remains a concern. association with all types of antibacterial medications.

The symptoms range from mild to severe diarrhea, pseudomembranous.

Colitis can advance to toxic megacolon and lead to deadly perforation of the colon.It is rare for medical conditions to be recorded before a child turns two years old. Neonates or infants may lack sufficient amounts. cellular processes for adhering to and breaking down the toxins generated by *Clostridium* bacteria. In a scenario with a high level of asymptomatic carriage, the detection of *C. difficile* toxin may not be assured.

It is the primary cause of diarrhea in children under 2 years old, particularly before they reach adolescence. decades of being. Defining infection and deciding on treatment in children can be challenging. CDIs are the most commonly observed healthcare-associated infections. In the United

States, CDIs account for more than half ofallcases.

Every year, 200,000 people are admitted to hospitals, resulting in 12,000 deaths and an additional $1 billion in healthcare costs. duration of one year.

More than 80% of deaths from CDI occur in individuals aged 65 and older. Most cases of CDI typically occur after.

The person is often given broad spectrum antibiotics, usually while in or soon after being hospitalized. hospital or nursing home. Broad spectrum antibiotics remove a significant amount of the bacteria that is currently in existence. the intestines create an optimal habitat for *C. difficile* bacteria to thrive and cause an infection. Ongoing studies being conducted by The CDC has announced a decrease of 30% in the spread of a disease. Using broad-spectrum antibiotics could lead to a 25% reduction in the rate of CDI among hospitalized patients. From 2011 onwards, there has been a decrease in CDI rates acquired in healthcare settings, but an increase in cases coming from the community. Increased focus on responsible use of antimicrobials likely resulted in a reduction in cases of CDIs.(4)

Experts in infection control have concluded that the most important measure to take is using gloves before practicing hand hygiene.

Prevent the spread of CDI in healthcare settings. Sharing information about patients' CDI status among different parties.

Having appropriate facilities is essential when moving patients with active CDI between health care settings. Similarly, however, human ingenuity has the power to conquer hindrances and hurdles.

Transfer form. Medical transport staff should also undergo appropriate training in dealing with infectious diseases.

The present state and necessary precautions. The need for contact tracing following a confirmed case of COVID-19 within their establishment.

An incident at a CDI facility or a scenario necessitating extra education or resources. Exchanging data on patients with *C. difficile* infection Assessing the patient's condition upon transfer is essential in order to avoid the transmission of *C. difficile* in healthcare facilities. facilities. CDI has become a significantly crucial phenomenon. Infection acquired in hospital settings In the year 2016, *C. difficile* was officially renamed as Clostridioides difficile, a Gram-positive, anaerobic, spore-forming, toxin-producing bacterium. New tag shows the differences in classification of this species. and other species belonging to the Clostridium genus (4) *C. difficile* spores can be transmitted via the fecal-oral route. The pathogen is frequently present in the surroundings and the method of transmission is extensive. Potential places where *C. difficile* may be located include people with no symptoms, individuals who have been infected, those withadisease contaminated surroundings and the intestines of animals Examples of animals include dogs, cats, pigs, and birds. Approximately 5% of Many adults and up to 70% of infants harbor bacteria in their bodies. *C. difficile*, with a high frequency of colonization occurrences times higher in patients who are hospitalized or residing in nursing homes residents (5) *C. difficile* was first discovered in a In 1935, Hall and O'Toole were the first to discuss the stool of a healthy newborn. It was seen as a rare microorganism until the 1970s, but it was always part of the normal gut microbiome. The role of antibiotics has been altered since they were first introduced. The contribution of C. difficile in the onset of illnesses in the colon.

CDI has emerged as one of the most crucial now. Hospital-acquired infections affect every department in healthcare institutions. CDI is the prevalent healthcare-associated infection, resulting in increased levels of sickness and mortality in hospitalized patients. Sources acquired in the community have been linked to as many as 29,000 reported deaths in the literature. In the same way, the increase in nosocomial infections has resulted in a $1.5 billion rise in healthcare costs in the United States. CDI outside of the intestines is less frequent than CDI within the intestines. Extraintestinal CDI has been observed in the

small intestine causing cellulitis, contributing to reactive arthritis, forming visceral abscesses, triggering septic arthritis, and resulting in empyema. Postoperative intra-abdominal abscess was often mentioned in cases of extraintestinal CDI (6) The individual experienced an uncommon instance of long-lasting abdominal wall abscess after a partial ileal resection, which resulted in a *C. difficile* infection caused by a single microorganism. Moreover, there is a lack of clear guidelines for treating extraintestinal CDI unlike the IDSA guidelines for intestinal CDI(7) Hence, the challenge of managing the condition remains challenging. Here, we discuss a rare case of CDI on the abdominal wall and the difficulties faced in treating the patient.

Recent studies show that the level of bacterial presence in... Patients infected with *C. difficile* (CDI) generally have higher levels of the bacteria compared to carriers, resulting in a lower cycle threshold(CT).Test for amplifying nucleic acids. Further analysis is required for the specific application of Quantitative NAAT using CT-values as a threshold.(8)

Conclusion

C. difficile, a bacteria causing serious infectious colon inflammation with high rates of illness and death globally, has managed to gain a presence in Asia. The rise of *C. difficile* cases with more dangerous strains in North America and Europe is likely to be seen in Asia in the future. While *C. difficile* testing is widespread in certain regions of Asia, there is a lack of literature emphasizing the importance of increased clinical and laboratory knowledge regarding this condition. Quick identification of this pathogen will aid in the necessary creation of infection prevention measures to prevent the spread of *C. difficile* in Asia.

In the last ten years, CDI has emerged as one of the most harmful. Hospital-acquired infections. Most important to recall is that Preventing CDI begins with educating healthcare professionals on preventive measures like handwashing and glove usage. using appropriate decontamination techniques for medical devices and the patient's environment, along with effective antibiotic management. risk of developing complications such as drug-resistant infections. greatest potential for developing CDI. FMT shows great potential as a treatment for CDI.

Clostridioides difficile is the primary reason for healthcare-associated infections and resulted in approximately 235,700 cases across the country in 2017. It is also considered the costliest healthcare-associated infection, contributing significantly to annual healthcare expenses. Extraintestinal CDI makes up 0.61% of total cases and typically targets the abdominopelvic area. Our patient had several risk factors, such as exposure to healthcare settings, antibiotic and proton pump inhibitor (PPI) use, GI surgery (often colon), and malignant tumors. The extraintestinal burden of CDI may be underestimated, given the anaerobic nature of the organism and reporting of coexisting organisms in polymicrobial infections.

Initially, she experienced an incarcerated parastomal hernia and bowel perforation necessitating partial ileal resection. Her abdomen was left open with an Abthera device for a week before the ostomy and abdomen were fully closed with mesh. Next, she resided in a long-term care facility until just a few days prior to her presentation. Thirdly, she was taking long-term PPI medication and additionally, she had diabetes mellitus, which is now being acknowledged as a risk factor for CDI in recent research.

The main cause of extraintestinal infection is fecal spillage resulting from gastrointestinal perforation. Therefore, numerous patients show polymicrobial infection containing *C. difficile*; this could indicate overflow of a colonizer rather than a true pathogen. Not all extraintestinal *C. difficile* strains are toxigenic for the same reason. The organism can also enter the mucosa without perforation, move into the bloodstream, and spread to other locations. Our patient, on the other hand, presented with a *C. difficile* abscess in the abdominal wall nearly six months after the initial event, despite typically presenting within four weeks for extraintestinal CDI cases. Her situation stood out because the first culture showed single-strain growth.

The management of extraintestinal CDI is intricate and lacks a clear definition. This is due to the fact that popular drugs like vancomycin and fidaxomicin, used for treating intestinal CDI, have limited absorption when taken orally, leading to insufficient levels of the medication in areas outside the intestines. Although metronidazole is effective when given orally, its prolonged use is restricted due to toxicity, therefore either oral or intravenous metronidazole (if not limited by toxicity), or intravenous vancomycin are utilized to effectively treat extraintestinal CDI. Many facilities do not have widespread access to antimicrobial susceptibility testing and customizing antibiotic regimens, with usage typically restricted to specialized institutes for epidemiological purposes. Sensitivity data for anaerobes like *C. difficile* is not typically available to guide specific antibiotic treatment.

To avoid intestinal CDI, she was also given oral vancomycin preventively during treatment with broad-spectrum antibiotics. Some evidence suggests that this approach is effective for preventing CDI in specific groups, but not for preventing it initially. Although the infection was successfully eradicated, the patient's treatment was complicated by septic shock, multiple hospital stays, and prolonged antibiotic treatment.

Reffrences:-

1. Magill, S.S., et al. 2014. Multistate Point-Prevalence Survey of Health Care-Associated Infections. New England Journal of Medicine, 370, 1198-1208.
2. Dubberke ,E.R., Carling,Ph., Carrico,R., Donskey,C.J., Loo,V.G., McDonald,L.C., Maragakis,L.L ., Sandora,Th.J., Weber,D.J., Yokoe,D.S., Gerding,D.N.2014. Strategies to prevent Clostridium difficile infections in acute care hospitals: Update. Infect Control Hosp Epidemiol;35(6):628-45.
3. Knight ,D.R., Imwattana ,K., Kullin ,B., Guerrero-Araya ,E., Paredes-Sabja ,D., Didelot ,X., Dingle ,K.E., Eyre ,D.W., Rodríguez ,C., Riley ,Th.V. 2021.Major genetic discontinuity and novel toxigenic species in *Clostridioides difficile* taxonomy eLife. 11;10
4. Imwattana,K., Knight,D.R., Kullin,B., Collins,D.A., Putsathit,P., Kiratisin,P & Riley,Th.V. 2019. *Clostridium difficile* ribotype 017 – characterization, evolution and epidemiology of the dominant strain in Asia, Emerging Microbes & Infections, 8:1, 796-807
5. Oren A., Garrity G.M 2017. List of new names and new combinations previously effectively, but not validly, published. Int J Syst Evol Microbiol 67:3140–3143
6. Lawson, P.A., Citron, D.M., Tyrrell, K.L., Finegold, S.M. 2016. Reclassification of *Clostridium difficile* as *Clostridioides difficile* (Hall and O'Toole 1935) Preevot 1938. Anaerobe 40:95–99
7. Leffler, D.A., Lamont, J.T .2015 *Clostridium difficile* infection. N Engl J Med 373:287–288
8. Hensgens, M.P., Goorhuis, A., Dekkers, O.M., Kuijper, E.J. 2012 Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 67:742–748